EMA Recommends Granting a Conditional Marketing Authorisation for Linvoseltamab By Ogkologos - April 10, 2025 426 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with relapsed and refractory multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR EMA Starts Review of Rucaparib May 19, 2022 Five Questions With…Amber. June 30, 2022 Improving Care for Underserved People With Cancer and Evaluating Delays in... September 20, 2021 Woman Diagnosed with Cancer a Week After Her Honeymoon Helps Others... June 2, 2021 Load more HOT NEWS ESMO Calls for Concerted Action to Prevent Burnout and Foster Well-Being... FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single... The team of over 60 scientists investigating the age-old mystery of... Mom Spots Strange Glow In Daughter’s Eye While Looking At Photo,...
